For those of you who may not be aware, Epidolex is a product made from cannabidiol (CBD) to control epilepsy. It is the very first cannabis-derived drug to be approved by the FDA. Today, doctors in every single one of the 50 states of the US can prescribe epidolex without having to worry about any form of legal prosecution whatsoever. Epidolex receiving the approval of the FDA means that federal authorities have finally acknowledged that a phyto-cannabinoid compound like CBD possesses therapeutic value. But what does this mean for businesses that deal with CBD? Before we take a look at that, why don’t we talk a little bit about the drug Epidolex?

What is Epidolex?
Epidolex is a drug – with its main ingredient being CBD – created to treat patients suffering from LGS – a severe type of epilepsy that becomes evident during childhood and is likely to persist through to adulthood. With CBD quite already becoming very popular among users because of its reported abilities to provide relief from pain, anxiety, stress, depression, sleep disorder and the likes, the approval of the drug Epidolex certainly sounds like good news to those plying their trade in the CBD industry.

Yet, while this good news is definitely something to welcome with open arms, not all CBD businesses are likely to benefit from it because of the type of CBD they may be producing.

The fact that you are trading in CBD doesn’t necessarily mean it’s from the correct source. Just because the FDA approved a CBD-made drug doesn’t mean all CBD compounds are acceptable. You see, there are two sources of CBD. CBD can be found either in the hemp plant or marijuana but what differentiates CBD from the hemp plant and that from marijuana is that in the hemp plant, there is a high amount of CBD and little THC, while in marijuana there is a small amount of CBD and high amounts of THC.

THC is the psychoactive chemical compound present in marijuana responsible for the mind-altering effects present in users of the substance. This, as such makes marijuana and THC illegal. The availability of THC in the hemp plant, however, is 0.3% or less. This means that while CBD derived from marijuana can be regarded as a federally controlled substance, CBD derived from the industrial hemp plant cannot. As long as CBD is from industrial hemp, it cannot be listed or viewed as a federally controlled substance, according to the Agricultural Act of 2014 (Farm Bill)

With the FDA affirming through their approval of epidolex that CBD does indeed have medicinal value, it can only mean good news for those who are in the hemp-derived CBD business. Already there are a number of studies and anecdotal evidence that indicate CBD is beneficial when it comes to improving the state of one’s health and so the FDA’s stamp of approval can only be expected to increase the clamour for CBD. This presents a massive opportunity for producers and retailers in the CBD business to make the most out of the compound by building on the F.D.A’s vote of confidence.

Those dealing with CBD produced from marijuana, they will have to tread cautiously and stay within frameworks regulated by the state.

It is important to note however that CBD products aren’t yet being regulated by the FDA. As a result, there is an influx of low-quality products in the system. While this can be problematic, it also presents an opportunity for those involved in selling high-quality products.